<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Shares of Crispr Therapeutics CRSP, +2.79% gained 3.1% in premarket trading on Wednesday after the company said the first patient had been dosed in a Phase 1 clinical trial evaluating the experimental type 1 diabetes treatment it developed with the privately held ViaCyte Inc. The investigational treatment uses ViaCyte’s stem cell-derived therapy in combination with Crispr’s gene-editing technology to generate pancreatic cells. Crispr’s stock has tumbled 61.0% over the past year, while the S&P 500 SPX, +0.69% has gained 20.4%.
...read full article on Market Watch
